MET-224o

all catalysts(0)

nothing on the calendar yet

News(2)

• Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructure
  The additional cuts, which will primarily occur between 2027 and 2029, will cost some $6 billion as the pharma tries to ride out a post-COVID headache while facing stiff patent headwinds for major…
  biospace · 16d ago
• Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout
  Pfizer has axed two clinical-stage obesity programs, dropping a GLP-1 receptor agonist from the Metsera buyout and a GIPR antagonist as part of its quarterly pipeline cleanout.
  fiercebiotech · 16d ago